Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | PPP5C | P53041 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20625191 | 1.00 | GABRR1 (0.39) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL2869805 | 1.00 | GABRR1 (0.39) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL17803105 | 1.00 | GABRR1 (0.39) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL7644053 | 0.84 | GABRR1 (0.37) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL7635619 | 0.84 | GABRR1 (0.37) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL19857354 | 0.84 | GABRR1 (0.37) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL2865585 | 0.84 | GABRR1 (0.37) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL2865583 | 0.84 | GABRR1 (0.37) | GABRR1SLC1A2SLC1A1GRM2GABRR2 | |
| SCHEMBL13503580 | 0.83 | GABRR1 (0.40) | GABRR1SLC1A2GRM2GABRR2PPP5C | |
| SCHEMBL11905774 | 0.83 | GABRR1 (0.40) | GABRR1SLC1A2GRM2GABRR2PPP5C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571351-B1 | DIAZENIUMDIOLATE CYCLOHEXYL DERIVATIVES | MERCK SHARP & DOHME (US) | 2016-09-14 | — | — | EP | disclosed |
| US-8623846-B2 | Diazeniumdiolate cyclohexyl derivatives | MERCK SHARP & DOHME CORP. (US) | 2014-01-07 | — | — | US | disclosed |
| US-20130059823-A1 | Diazeniumdiolate Cyclohexyl Derivatives | MERCK SHARP & DOHME LLC | 2013-03-07 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-7842361-B2 | Oxygen-absorbing resin, oxygen-absorbing resin compositions and oxygen-absorbing containers | TOYO SEIKAN KAISHA, LTD. (JP) | 2010-11-30 | — | — | US | disclosed |
| US-20090098323-A1 | OXYGEN-ABSORBING RESIN, OXYGEN-ABSORBING RESIN COMPOSITIONS AND OXYGEN-ABSORBING CONTAINERS | TOYO SEIKAN KAISHA, LTD. (JP) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059823-A1 | Diazeniumdiolate Cyclohexyl Derivatives | OR10J3, CBR3, CBR1 | GABRR1 277/4885SLC1A2 2785/4885SLC1A1 1387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.